Experts Weigh In on the Dangers of Importing Foreign Price Controls

Posted

BIOtech Now Andrew Segerman Experts recently gathered on Capitol Hill to discuss how importing foreign price controls will lead to less innovation and less patient access to breakthrough treatments. Leaders in biotech innovation, as well as within the patient community, have been sounding the alarm over a Trump-administration proposal that would tie drug prices in […]

New Videos Show How “Fail First” Policies Can Fail Patients

Posted

BIOtech Now BIOtechNOW Editor Continued access to a stable treatment can make all the difference for patients with chronic illnesses like arthritis, cancer, diabetes, hepatitis C, HIV/AIDs and more.  Interruptions in treatment can lead to disease progression and unnecessary medical expenses like hospitalization or surgery. In rheumatoid arthritis, studies show delaying treatment can lead to significantly more […]

Rare Disease Drug Development Increases but Challenges Remain

Posted

BIOtech Now Andrew Segerman In a recent study published by Tufts University, researchers found that rare disease drug development is now one of the fastest growing areas in drug R&D, with nearly one-third of all products in the global R&D pipeline targeting treatments for rare disease indications. Yet while innovative biopharmaceutical companies have increased R&D […]

A Sustainable Movement to Curb Cancer in Africa

Posted

BIOtech Now admin In just two years, BIO Ventures for Global Health (BVGH) has made significant progress in responding to the growing cancer crisis in Africa. Through their African Access Initiative (AAI), this nimble, Seattle-based non-profit has established partnerships with industry giants, Pfizer and Takeda Pharmaceuticals, Ministries of Health in six African countries and hospital […]

New BIO White Paper: Incorporating Real-World Evidence Within the Label of an FDA-Approved Drug

Posted

BIOtech Now Sesquile Ramon In today’s increasingly connected world, health care researchers have access to previously unimaginable troves of data about the effects of healthcare interventions, including medicines. New technologies are allowing researchers to use so-called “big data” to investigate ways to better diagnose disease, predict which patients will benefit from which therapies, and observe […]

The DISARM Act Can Help Fix the Broken Antibiotics Market

Posted

BIOtech Now Andrew Segerman In his a recent piece for Bloomberg, reporter Robert Langreth paints a harrowing picture of the quickly deteriorating antibiotics market and calls attention to the challenging ecosystem biopharmaceutical innovators and investors are having to deal with – or increasingly, moving away from altogether: “The business model, the way we reimburse and […]

AI Helps Unravel Mystery of Neurological Disorders

Posted

BIOtech Now Jeremy Isenberg Neurological disorders are estimated to affect up to 1 billion people around the world—including nearly 100 million Americans—with roughly 7 million people dying of the maladies every year worldwide. The vast spectrum of more than 600 neurological disorders includes Alzheimer’s, Parkinson’s disease, strokes, multiple sclerosis, epilepsy, migraines and brain injuries. These […]

BIO 2019 Wraps Up in Philadelphia

Posted

BIOtech Now Theresa Brady “The world is beginning to grasp that we’ve entered the dawn of a golden age of medicine. It’s an age of hope. It’s an age of possibility. And it’s an age of healing. No disease will escape our scientists anymore. None.” – Jim Greenwood, CEO of Biotechnology Innovation Organization (BIO) Convention […]

U.S. as a Global Leader for Patient Access

Posted

BIOtech Now BIOtechNOW Editor Some 95 percent of cancer drugs launched around the globe are available in the U.S. Given that the U.S. is a global leader in ensuring patients have access to the newest therapies, the country has a profound impact on patient treatment and outcomes around the world. During the panel, Global Perspectives […]

Opioids: Changing the Paradigm of Treating Pain and Addiction—One Year Later

Posted

BIOtech Now Jeremy Isenberg Drug overdose deaths, including those involving opioids, reached 42,000 in 2016 (CDC), prompting a national response from the healthcare community to the sprawling crisis. The rise of opioid deaths appears to have occurred in three waves: first prescription opioids, followed by heroin, and most recently, synthetic opioids. The community recognized that […]

BIO 2019 Innovation Zone Company Snapshot: Litron Laboratories

Posted

BIOtech Now Andrew Segerman The next big medical breakthrough is on the horizon and all it takes is one idea, one vision, or one conversation for a small, emerging biotech to change the way we treat and cure diseases for generations to come. Recognizing the potential and promise of early-stage companies for addressing unmet medical […]

BIO 2019 Innovation Zone Company Snapshot: HealthRhythms, Inc.

Posted

BIOtech Now Andrew Segerman The next big medical breakthrough is on the horizon and all it takes is one idea, one vision, or one conversation for a small, emerging biotech to change the way we treat and cure diseases for generations to come. Recognizing the potential and promise of early-stage companies for addressing unmet medical […]

Important Perspectives on Innovation and Costs

Posted

BIOtech Now Dan Durham This is an exciting time in biomedical innovation. New and highly innovative therapies are coming to market that promise significant improvements in patient health. They include a range of novel approaches to treating disease, like gene therapy, immunotherapy, and RNA interference. Many of the most transformative new therapies are designed to […]

New BIO Report on State of Innovation for Alzheimer’s Disease Therapeutics

Posted

BIOtech Now Andrew Segerman Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s Disease Therapeutics. This report, the fourth in a series on the innovation landscape of highly prevalent, chronic diseases, takes an in-depth look at the state of innovation for therapeutics in Alzheimer’s disease, which […]

“Health care’s big spending mismatch”

Posted

BIOtech Now Andrew Segerman This week, Axios reported on new data that shows “the health care services that rack up the highest out-of-pocket costs for patients aren’t the same ones that cost the most to the health care system overall.” While hospital care eats up the lion’s share of health care spending—a staggering $1.1 trillion—just […]

New Guide to Help Consumers Navigate Genetic Health Testing

Posted

BIOtech Now Jeremy Isenberg In recent years, we have seen a growing array of direct-to-consumer (DTC) genetic testing products rise to the fore. These tests are emblematic of a new era of healthcare that puts patients at the center of decision-making, allowing all of us to be more engaged in our personal healthcare. The uptake […]

Promising Results Offer Hope in Fight Against Candida auris

Posted

BIOtech Now Andrew Segerman While health care conversations on Capitol Hill today are largely focused on how to best lower overall and patient out-of-pocket spending, one area of focus that could have tremendous societal and personal implications in the coming years is unfortunately receiving scant attention: the rise of antimicrobial resistance (AMR). This “silent killer” […]

WSJ: Drug Importation is “Impractical, Unsafe and Unlikely” to Lower Prices

Posted

BIOtech Now Andrew Segerman This week, Editorial Board writers for The Wall Street Journal examined a policy proposal in Florida to import prescription drugs from Canada. But as the writers warn, such a move would be “impractical, unsafe and unlikely” to reduce prices for patients and consumers at the pharmacy counter. “When federal importation was […]